Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Q24243521)

8

0 references

Andreas Laupacis

7

object named as

Andreas Laupacis

0 references

author name string

Paul A Carless

2

0 references

Annette J Moxey

3

0 references

Dianne O'Connell

4

0 references

Barrie J Stokes

5

0 references

Brian McClelland

Cochrane Database of Systematic Reviews

6

0 references

publication date

17 October 2007

0 references

published in

0 references

cites work

Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red blood cell transfusion: results of a meta-analysis. International Study of Perioperative Transfusion (ISPOT) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin--are there lessons learned?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Prospective randomized placebo-controlled trial of aprotinin for elective aortic reconstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: a randomized clinical study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

[The effects of aprotinin. Blood loss and coagulation parameters in orthotopic liver transplantation: A clinical-experimental, prospective and randomized double-blind study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Does aprotinin influence endothelial-associated coagulation in cardiac surgery?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Bone bleeding during total hip arthroplasty after administration of tranexamic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Prophylactic tranexamic acid in elective, primary coronary artery bypass surgery using cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: a prospective randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

High-dose aprotinin: hemostatic effects in open heart operations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Defining the role of aprotinin in heart transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Double-orifice right atrioventricular valve associated with partial atrioventricular septal defect.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

"Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first-time coronary operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin and dipyridamole for the safe reduction of postoperative blood loss

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Management of bleeding complications in redo cardiac operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin versus lysine analogues: the debate continues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin and tranexamic acid for high transfusion risk cardiac surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Recombinant aprotinin in coronary artery bypass graft operations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Postoperative use of aprotinin in cardiac operations: an alternative to its prophylactic use

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Low-dose and high-dose aprotinin improve hemostasis in coronary operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effects of minimal-dose aprotinin on coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Additional postbypass administration of tranexamic acid reduces blood loss after cardiac operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Operations on the thoracic aorta and hypothermic circulatory arrest: is aprotinin safe?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Comparative study of antifibrinolytic drugs in orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effect of aprotinin on need for blood transfusion after repeat open-heart surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Economic evaluations of technologies to minimize perioperative transfusion: a systematic review of published studies. International Study of Peri-operative Transfusion (ISPOT) investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The effect of tourniquet application, tranexamic acid, and desmopressin on the procoagulant and fibrinolytic systems during total knee replacement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reduced blood loss by aprotinin in thoracic surgical operations associated with high risk of bleeding. A placebo-controlled, randomized phase IV study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in patients undergoing coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Economic analysis of erythropoietin use in orthopaedic surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid in aortic valve replacement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Heparin-bonded cardiopulmonary bypass circuits reduce the rate of red blood cell transfusion during elective coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin reduces blood loss and the need for transfusion in orthognathic surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin--preliminary results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Does aprotinin really reduce blood loss in orthotopic liver transplantation?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

1 reference

7 January 2021

Aprotinin in cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The risk associated with aprotinin in cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces postoperative bleeding in off-pump coronary artery bypass grafting.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Use of aprotinin in knee replacement surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin does not impair renal haemodynamics and function after cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Influence of High-dose Aprotinin Treatment on Blood Loss and Coagulation Patterns in Patients Undergoing Myocardial Revascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The dose-response relationship of tranexamic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

White-blood-cell-containing allogeneic blood transfusion, postoperative infection and mortality: a meta-analysis of observational 'before-and-after' studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The independent association of massive blood loss with mortality in cardiac surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Randomized, placebo-controlled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Tranexamic acid reduces bleeding after cardiopulmonary bypass when compared to epsilon aminocaproic acid and placebo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin-treated patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

International aspects of the AIDS/HIV epidemic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

High-dose aprotinin in cardiac surgery--a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Con: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The impact of aprotinin on coronary artery bypass graft patency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Prophylactic treatment of postperfusion bleeding using EACA.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

The efficacy and safety of aprotinin for hemostasis during intracranial surgery.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Does aprotinin reduce blood loss in total hip arthroplasty?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001886.PUB2

7 January 2021

Blood Conservation Techniques and Platelet Function in Cardiac Surgery

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1097/00000542-199109000-00008

Identifiers

DOI

10.1002/14651858.CD001886.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

3696638

3696638

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference